NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis $1.38 +0.01 (+0.73%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.31▼$1.4150-Day Range$1.07▼$1.7552-Week Range$0.41▼$1.93Volume912,287 shsAverage Volume2.06 million shsMarket Capitalization$253.95 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Nektar Therapeutics alerts: Email Address Nektar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside117.4% Upside$3.00 Price TargetShort InterestBearish5.44% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.50Based on 5 Articles This WeekInsider TradingSelling Shares$165,089 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.84) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.74 out of 5 starsMedical Sector255th out of 936 stocksPharmaceutical Preparations Industry114th out of 436 stocks 3.1 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Nektar Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.44% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Nektar Therapeutics has recently increased by 140.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 2.5 News and Social Media Coverage News SentimentNektar Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $165,089.00 in company stock.Percentage Held by InsidersOnly 3.71% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nektar Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nektar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Nektar Therapeutics Stock (NASDAQ:NKTR)Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Read More NKTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTR Stock News HeadlinesJuly 23 at 8:18 PM | msn.comB. Nektar Announces Their Latest ReleasesJuly 23 at 3:33 AM | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Hold" from AnalystsJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 18, 2024 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving Average of $1.08June 12, 2024 | prnewswire.comNektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024May 30, 2024 | prnewswire.comNektar Management to Present at Upcoming Investor ConferencesMay 24, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)May 11, 2024 | uk.finance.yahoo.comQ1 2024 Nektar Therapeutics Earnings CallJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 10, 2024 | finance.yahoo.comNektar Therapeutics (NKTR) First Quarter 2024 Earnings OverviewMay 10, 2024 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.comNKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024May 9, 2024 | markets.businessinsider.comNektar Therapeutics Q1 Loss Drops In Line With EstimatesMay 9, 2024 | washingtonpost.comNektar: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comNektar Therapeutics Reports First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Nektar Therapeutics's earningsMay 2, 2024 | prnewswire.comNektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsApril 24, 2024 | globenewswire.comBiolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune DiseasesSee More Headlines Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees137Year Founded1990Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$6.00 Low Stock Price Target$1.00 Potential Upside/Downside+117.4%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,060,000.00 Net Margins-195.02% Pretax Margin-195.21% Return on Equity-107.31% Return on Assets-38.08% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio5.79 Sales & Book Value Annual Sales$90.12 million Price / Sales2.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book2.00Miscellaneous Outstanding Shares184,020,000Free Float177,193,000Market Cap$253.95 million OptionableOptionable Beta0.66 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Howard W. Robin (Age 71)CEO, President & Director Comp: $1.83MMr. Mark A. Wilson (Age 52)Senior VP, Chief Legal Officer & Secretary Comp: $749.99kDr. Jonathan Zalevsky Ph.D. (Age 49)Chief Research & Development Officer Comp: $1.25MMs. Sandra A. Gardiner (Age 58)Interim Chief Financial Officer Vivian WuDirector of Investor Relations & Corporate AffairsMr. Robert BacciSenior Vice President of Human Resources & Facilities OperationsMs. Jennifer RuddockChief Business OfficerDr. Mary Tagliaferri L.Ac. (Age 58)M.D., Chief Medical Officer More ExecutivesKey CompetitorsADC TherapeuticsNYSE:ADCTAtea PharmaceuticalsNASDAQ:AVIRSeres TherapeuticsNASDAQ:MCRBPacira BioSciencesNASDAQ:PCRXOmerosNASDAQ:OMERView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 532,663 shares on 7/26/2024Ownership: 0.300%Values First Advisors Inc.Bought 45,197 shares on 7/19/2024Ownership: 0.025%SG Americas Securities LLCBought 28,338 shares on 7/12/2024Ownership: 0.040%Robert ChessSold 19,500 sharesTotal: $23,400.00 ($1.20/share)Lynx1 Capital Management LPBought 139,644 shares on 5/30/2024Ownership: 1.127%View All Insider TransactionsView All Institutional Transactions NKTR Stock Analysis - Frequently Asked Questions How have NKTR shares performed this year? Nektar Therapeutics' stock was trading at $0.5650 at the start of the year. Since then, NKTR stock has increased by 144.2% and is now trading at $1.38. View the best growth stocks for 2024 here. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.03. The biopharmaceutical company earned $21.64 million during the quarter, compared to analyst estimates of $14.91 million. Nektar Therapeutics had a negative net margin of 195.02% and a negative trailing twelve-month return on equity of 107.31%. What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees. Who are Nektar Therapeutics' major shareholders? Top institutional investors of Nektar Therapeutics include Bank of New York Mellon Corp (0.30%), SG Americas Securities LLC (0.04%) and Values First Advisors Inc. (0.02%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Jillian B Thomsen, Gil M Labrucherie, Mark Andrew Wilson, Jonathan Zalevsky, Robert Chess, Roy A Whitfield, Myriam Curet and John Northcott. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE) and Advanced Micro Devices (AMD). This page (NASDAQ:NKTR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
